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Abstract Diabetes is a significant public health burden
on the basis of its increased incidence, morbidity, and
mortality. This study aimed to estimate the prevalence of
inadequate glycaemic control and its correlates in a large
multicentre survey of Brazilian patients with diabetes. A
cross-sectional study was conducted in a consecutive
sample of patients aged 18 years or older with either type 1
or type 2 diabetes, attending health centres located in ten
large cities in Brazil (response rate = 84%). Information
about diabetes, current medications, complications, diet,
and satisfaction with treatment were obtained by trained
interviewers, using a standardized questionnaire. Glycated
haemoglobin (HbA1c) was measured by high-performance
liquid chromatography in a central laboratory. Patients with
HbA1c C 7 were considered to have inadequate glycaemic
control. Overall 6,701 patients were surveyed, 979 (15%)
with type 1 and 5,692 (85%) with type 2 diabetes. The
prevalence of inadequate glycaemic control was 76%. Poor
glycaemic control was more common in patients with type
1 diabetes (90%) than in those with type 2 (73%),
P \ 0.001. Characteristics significantly associated with
improved glycaemic control included: fewer years of dia-
betes duration, multi professional care, participation in a
diabetes health education program, and satisfaction with
current diabetes treatment. Despite increased awareness of
the benefits of tight glycaemic control, we found that few
diabetic patients in Brazil met recommended glycaemic
control targets. This may contribute to increased rates of
diabetic complications, which may impact health care
costs. Our data support the public health message of
implementation of early, aggressive management of
diabetes.
Keywords Glycaemic control  HbA1c 
Diabetes mellitus  Epidemiology  Brazil
Introduction
Diabetes is one of the most prevalent non-communicable
diseases globally, presenting a significant public health
burden on the basis of its increasing incidence, morbidity,
mortality, and economic costs [1–3]. In 2000, estimates
from World Health Organization indicated that there were
*170 million people in the world with diabetes, and until
2030, it is expected that the number of cases of the disease
worldwide will have more than doubled to 366 million [2].
In the Americas, the number of diabetes cases will change
from 33 million to 66.8 million in the same period [2].
Diabetes is associated with serious long-term complica-
tions including microvascular and macrovascular disease,
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which impose an additional socio-economic burden and
account for substantial healthcare costs [1, 3–6].
Evidence from key controlled studies conducted in the
past decade established the importance of tight and sus-
tained glycaemic control among type 1 and 2 diabetic
patients [7, 8]. These studies have emphasized the central
role of consistently managing HbA1c levels in patients with
diabetes, as a result, some professional associations pro-
posed clinical guidelines in the range of 6.5–7.0% to
motivate health professionals and patients to constantly
manage blood glucose levels [9, 10]. Despite the numerous
advances achieved in diabetes control and evaluation, the
management of such a complex disease remains challeng-
ing. Recent epidemiological data from various regions of
the world show most patients with diabetes are not con-
trolled to recommended HbA1c targets [11–21]. In addition,
estimates of prevalence of inadequate glycaemic control
vary widely, in part due to differences in diabetes type,
populations surveyed, methods used to collect data, and
goals of glycated haemoglobin (HbA1c).
Information about the epidemiology of diabetes in
Brazil is scarce and limited. According to a Brazilian
study [22], diabetes is the fifth most common reason for
hospitalizations and ranks among the 10 major causes of
mortality [22]. Thus, diabetes is a major problem in
Brazil, with an impact on public heath comparable to that
in more developed countries. Knowledge on glycaemic
control is of great relevance for planning healthcare
programs targeting improved diabetes control. The aim of
this study was to estimate the prevalence of inadequate
glycaemic control and its correlates in a large multicentre
survey of adult patients with type 1 or type 2 diabetes in
Brazil.
Materials and methods
Setting and participants
This was a cross-sectional and nationwide survey con-
ducted from February 2006 to March 2007. It was designed
to obtain detailed information about glycaemic control and
its determinants in the largest possible sample of diabetic
adults living in urban areas in Brazil. Study design and
reporting format are in accordance with the recommended
STROBE (Strengthening the Reporting of Observational
Studies in Epidemiology) guidelines [23]. As it was not
feasible to contact patients directly, the study was based on
outpatient diabetes clinics. These centres were located in
10 cities belonging to four Brazilian regions, as follows:
Southeast (Belo Horizonte, Campinas, Rio de Janeiro, and
Sa˜o Paulo), South (Curitiba and Porto Alegre), Mid-west
(Brası´lia), and Northeast (Salvador, Fortaleza, and Recife).
The cities included were the largest in their respective
regions and nine of them are ranked among the most
populous municipalities in Brazil. For the recruitment of
diabetes centres, we asked the Brazilian Diabetes Associ-
ation to identify in each of the participating cities a list of
candidate centres, to be chosen from those with longer
experience in epidemiological research and where at least
300 adult patients with diabetes were followed per month.
According to these criteria, each city contributed with two
centres for the sampling of the study participants. All 20
centres invited joined the study; they were classified as a
university-affiliated hospital (5), a general public hospital
(11), or not-for-profit private hospital (4).
Study population
We selected a sample of all consecutive patients with
diabetes mellitus attending each participating clinic during
a 30-day period. Eligible cases were adults aged 18 years
or older, who had been previously diagnosed by a physi-
cian with either type 1 or type 2 diabetes before the survey.
Patients who had participated in an intervention trial in the
previous 3 months and women who reported a history of
diabetes only during pregnancy were not included. Each
centre was asked to recruit at least 150 patients. Overall,
the response rate was 84% (ranging from 78 to 95%). All
participants provided written informed consent, and the
study protocol was approved by Ethical Review Boards in
each respective city.
Data and specimens collection
A structured questionnaire was administered in person by
trained and certified interviewers, not part of the study
centre staff. A team of study interviewers was hired and
trained by one of the investigators (EDM) in each partici-
pating centre. They were given an orientation on the pro-
tocol and specific details concerning participation in the
study. Prior to study commencement, they all carried out
practice sessions with authentic respondents. These pre-
liminary interviews were observed and critiqued by the
investigators.
The study questionnaire sought information about dia-
betes history and main characteristics of each patient. This
included self-reported data on socio-demographic and
disease factors (age, sex, educational level, marital status,
duration of diabetes, number of diabetes-related disorders,
etc.); clinical parameters (fasting blood glucose, HbA1c,
body mass index [BMI], and blood pressure); and factors
related to treatment processes such as actual treatment for
diabetes, adherence to treatment, and access to multi pro-
fessional care (defined as health care delivered by a team
comprised by at least, an Endocrinologist or diabetes
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specialist, a Nurse, and a Dietitian or Nutritionist). In
addition, we also gathered information on self-perception
of glycaemic control (using a scale with four levels: poor,
fair, good, and very good), and satisfaction with current
diabetes treatment (using a single global question: ‘‘If you
were to spend the rest of your life with your diabetes
treatment the way it is today, how would you feel about
this? Very satisfied, somewhat satisfied, neither dissatisfied
nor satisfied, somewhat dissatisfied, or very dissatisfied’’).
The questionnaire was piloted on a sample of volunteer
patients to refine the wording of items and ensure clarity
of the text. All items were assessed for face validity by
health survey experts. The individual interviews lasted an
average 20–25 min, and the sessions occurred in a private
room.
A peripheral blood sample was collected for the
measurement of HbA1c in every patient. All measurements
of HbA1c were made with an automated high-performance
liquid chromatography (Variant Turbo—BioRad) in a
central laboratory. The normal value range is 4.0–6.0%.
Statistical analysis
All collected data were double-entered into a computerized
database using a word processing, database, and statistics
program (EPI INFO version 3.04d, centres for Disease
Control & Prevention, USA; World Health Organization,
Geneva, Switzerland) with custom-designed algorithms
and cross-checks to verify for correctness and internal
consistency. The number and percent of diabetic patients
who achieved glycaemic control were calculated using a
cutpoint HbA1c \ 7.0%, as defined in the American Dia-
betes Association standards of medical care for persons
with diabetes [24]. The values of HbA1c were also classi-
fied into three arbitrary categories: \7.0%, 7.0–8.9% and
C9.0%. The data presented were stratified by diabetes type
(1 or 2) and by diabetes duration (\5 years and C5 years).
In some analysis, the data on type 2 diabetes were further
stratified by therapeutic regimen in two categories: insulin-
treated and non-insulin-treated. Basic descriptive statistics
and frequency calculations were performed on all vari-
ables; a chi-square test was used to assess differences in
answers by categories of stratifying variables, with statis-
tical significance at 5%. All statistics analyses were per-
formed using the ‘‘R’’ statistical software (Version 2.5.0;
The R Foundation for Statistical Computing, Vienna,
Austria).
Results
Overall 6,701 patients were included in this survey, 979
(15%) with type 1 and 5,692 (85%) with type 2 diabetes.
The characteristics of the study participants are shown in
Table 1. The age ranged from 18 to 98 years, approxi-
mately 40% of the patients with type 1 diabetes were
younger than 35 years, whereas almost all patients with
type 2 diabetes were 35 years or older. Most of the study
participants were females, married or living with a partner,
white, and had attained primary school education or less,
regardless of diabetes type. The distribution of BMI cate-
gories among the patients with type 1 diabetes revealed that
Table 1 Selected characteristics (%) of 6,671 patients, according to
diabetes type, Brazil, 2006
Diabetes
Type 1
(n = 979)
Type 2
(n = 5,692)
Age in years
\25 18.6 0.2
25–34 21.0 0.8
35–44 21.9 5.6
45–54 19.6 21.5
55–64 13.8 34.7
C65 5.1 37.2
Female 63.8 66.5
Current marital status
Married/living with partner 46.4 58.5
Single, never married 39.9 14.2
Divorced/separated 7.5 8.9
Widowed 6.2 18.4
Racial/ethnic background
White 49.9 45.2
Mixed 35.3 41.1
Black 12.7 12.3
Other 2.1 1.4
Education
Primary school or less 40.8 72.7
Secondary/high school 43.4 18.7
At least some college 15.8 8.6
Body Mass Index (Kg/m2)
Underweight (B18.5) 4.4 1.6
Normal weight (18.6–24.9) 47.6 28.2
Overweight (25.0–29.9) 32.6 39.8
Obese (30.0–39.9) 13.6 27.9
Morbidly obese (C 40.0) 1.8 2.5
Multi professional carea 83.4 50.5
Number of diabetes-related complications
None 34.1 24.0
1 25.7 30.9
2 20.6 25.1
C3 19.6 20.0
a Comprised at least: an Endocrinologist (or diabetes specialist), a
Nurse, and a Dietitian (or Nutritionist)
Acta Diabetol (2010) 47:137–145 139
123
47.6% were classified as normal weight and 15.4% as
obese compared to 28.2 and 30.4% among the patients with
type 2 diabetes, respectively. Health care delivered by a
multi professional team was reported more often by
patients with type 1 diabetes (83.4%) than by patients with
type 2 diabetes (50.5%).
The prevalence of diabetic patients with inadequate
glycaemic control (HbA1c C 7.0%) was 76% (5,044/
6,671). Table 2 shows the frequency distribution of HbA1c
values in the population studied according to diabetes type
and duration. Poor glycaemic control was more common in
patients with type 1 diabetes (90%) than in those with type
2 (73%), P \ 10-3. However, the distribution of HbA1c
values in patients with type 2 diabetes (insulin-treated)
resembled that found in type 1 patients; whereas patients
with type 2 diabetes (non-insulin-treated) were more likely
to have a higher prevalence of adequate glycaemic control
(35.7%) when compared to patients with type 1 (10.4%) or
type 2 (insulin-treated) (9.7%), P \ 10-3. After stratifying
the data by diabetes duration, patients with either diabetes
type 1 or 2 lasting 5 years or more were more likely to have
worse control than those whose diabetes started \5 years
(Table 2).
The frequency distribution for categories of HbA1c
values by selected characteristics and diabetes type is
summarized in Table 3. There was no significant difference
in glycaemic control according to gender, except for type 2
patients (insulin-treated), where females were nearly twice
more likely to have adequate glycaemic control (13.1%)
than males (7.8%) (P \ 0.001). Patients with type 1 dia-
betes or with type 2 diabetes (insulin-treated) cared by a
multi professional team were less likely to present HbA1c
values in the highest categories than those receiving non-
specialist care (Table 3). The self-perception of glycaemic
control was associated with HbA1c levels, regardless of
diabetes type. Hence, patients who perceived their gly-
caemic control to be ‘‘poor’’ or ‘‘fair’’ were more likely to
fall in the top category of HbA1c values, conversely,
patients perceiving their glycaemic control to be ‘‘good’’ or
‘‘very good’’ were more likely to have adequate glycaemic
control and to be classified in the lower category of HbA1c
values (\7.0%). Ever participating in a group or pro-
gramme that promotes diabetes health education was
associated with lower rates of elevated HbA1c values in
patients with type 1 diabetes, but there was no significant
difference among patients with type 2 diabetes (Table 3).
The reported satisfaction with current diabetes treatment
was directly associated with glycaemic control (Fig. 1).
Diabetic patients satisfied with their treatment were more
likely to have adequate glycaemic control. This was more
evident in patients with type 2 diabetes (non-insulin-trea-
ted), but was also seen among patients with type 1 diabetes
and type 2 diabetes (insulin-treated). T
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Discussion
To our knowledge, this is the largest multicentre, nation-
wide survey to estimate prevalence rates of inadequate
glycaemic control in Brazil, and the first to evaluate these
rates in patients with type 1 or type 2 diabetes. The overall
prevalence of inadequate glycaemic control in our study
(76%) was high, and greater than previous estimates from
studies in Germany (40%) [18], Denmark (51%) [14], and
Kenya (61%) [17], which also included type 1 and 2 dia-
betic patients.
The rates of inadequate glycaemic control were higher
in patients with type 1 diabetes (90%) than in patients with
type 2 diabetes (73%). Among the latter group, patients
without insulin in their therapeutic regimen had lower rates
of poor glycaemic control (64%). While patients using
insulin presented a prevalence of inadequate glycaemic
control (90%) similar to that found in patients with type 1
diabetes. These differences changed after we stratify the
data by diabetes duration, but even among patients at
earlier stage of diabetes (\5 years duration) insulin treat-
ment is associated with worse control when compared to
diet alone or combined with oral treatment, possibly due to
more severe and more difficult to control diabetes in the
former patients. Furthermore, patients using oral treatment
(the major option in the group ‘‘non-insulin-treated’’) have
a more simple to administer treatment option, which tends
to be more effective under the conditions of daily life.
Our rates of inadequate glycaemic control in patients
with type 2 diabetes are higher than those reported in the
same type of diabetic patients in the United States, where
estimates derived from the National Health and Nutrition
Examination Survey [NHANES] were 63% (1999–2000),
51% (2001–2002), and 43% (2003–2004) [25]. Similarly,
reports from Canada (49%) [13], and the Netherlands
(42%) [26] also revealed rates of poor glycaemic control in
type 2 diabetes lower than ours. However, recent surveys in
patients with type 2 diabetes in the United Kingdom [UK]
(N = 10,663) [12] and Canada (N = 5,569) [20] provided
estimates of inadequate glycaemic control closer to ours,
76 and 73%, respectively. Although these variations across
studies may be true, they may also be due to differences in
populations surveyed, methods of data collection, mea-
surements of HbA1c, and definitions of HbA1c cutpoint for
adequate glycaemic control.
In our data, there was no significant difference in gly-
caemic control by gender, except among patients with type
2 diabetes (insulin-treated), where women achieved a better
glycaemic control. In contrast, a study in a Pakistani
moslem diabetic population in Manchester, UK, women
were worse than men in performing regular glucose mea-
surements, in managing persistent hyperglycaemia, and
had poorer glycaemic control overall [27]. Results from a
survey in Mexico have suggested that women have several
social disadvantages, deterioration of healthy life, poor
self-care, and lack of solidarity that increases their vul-
nerability to reach glycaemic control successfully [28].
However, several studies have failed to show significant
gender differences related to self-care and control of type 2
diabetes [12, 20, 25, 26].
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We found that health care delivered by a multi profes-
sional team was associated with improved glycaemic
control in patients with type 1 diabetes or with type 2
diabetes (insulin-treated). Our results are consistent with
previous studies comparing primary with specialist diabe-
tes care [16, 20, 26, 29]. In the Pittsburgh Epidemiology of
Diabetes Complications Study, specialist care was associ-
ated with higher levels of participation in diabetes self-care
practices and a lower HbA1 level, but in the multivariate
analyses the lower HbA1 levels observed in patients
receiving specialist care were restricted to patients with an
annual income [$20,000 [30]. Possible explanations for
the better HbA1c seen with prior multi professional care
include greater access to other health care providers such as
nurse educators or dietitians, greater focus on glycaemia
management, or more aggressive use of glucose-lowering
medications by specialists.
There is evidence that poor numeracy skills are common
in patients with diabetes, and that low diabetes-related
numeracy skills are associated with fewer self-management
behaviours, and possibly poorer glycaemic control [31].
Diabetes self-management education programs are con-
sidered an essential strategy for improving health behaviors
of adults with diabetes. In a study to estimate the impact of
participation in a diabetes health education program on
glycaemic levels, Roblin et al. [32] reported that partici-
pation significantly improved glycaemic levels between
baseline and follow-up periods. Our findings suggest that
participation in a diabetes health education programme is
associated with lower HbA1c values in patients with type 1
diabetes, but we failed to show that among patients with
type 2 diabetes. However, our assessment was limited to
whether the patient had ever participated in a diabetes
health education program, and did not differentiate subjects
according to the amount of time and/or effort dedicated to
such programs.
Among the participants in our survey, self-perception of
glycaemic control was associated with HbA1c levels. That
is, patients who perceived their glycaemic control to be
‘‘poor’’ or ‘‘fair’’ were more likely to present higher HbA1c
values. This awareness may result from several reasons
including: the patients experiencing adverse symptoms
associated with hyperglycaemia, the patients’ knowledge
about their actual adherence to diet and antidiabetic med-
ication, and/or the patients’ information of their recent
HbA1c results. Unsurprisingly, we also found that global
satisfaction with current diabetes treatment was associated
with improved glycaemic control. It has been shown that
improvement in patient convenience provides better com-
pliance with therapeutic regimen and greater patient sat-
isfaction, and this in turn leads to better glycaemic control
[33–36].
Strengths and limitations
The distinctive strengths of this study are the large multi-
centre sample, the collection of data by trained and certi-
fied interviewers (not part of the staff at each study centre),
the measurement of HbA1c by a reliable method in a central
laboratory, and the high response rate (84%). This high
response was accomplished by rigorous training of inter-
viewers, who were selected based on interpersonal skills
displayed in previous surveys. Despite that, one limitation
is that the study was centre based, and while our sample
might be representative of patients with diabetes attending
health care facilities in Brazil, it may not be representative
of the whole population of Brazilian patients with diabetes.
Conclusion
Despite clinical evidence supporting tight control of diabetes
and increased awareness of the benefits of improved meta-
bolic control, we found that few diabetic patients in Brazil
met recommended glycaemic control targets. A large pro-
portion of patients with either type 1 or type 2 diabetes were
inadequately controlled. This may contribute to increased
rates of diabetic complications, which will impact health
care costs. Our data support the public health message of
implementation of early, aggressive management of diabe-
tes. The reasons for a worse metabolic control in patients
treated with insulin are not evident in our data. One may
argue that poor adherence to insulin and/or some degree of
inertia to apply the best currently available treatment regime
in patients who need insulin might account for this finding.
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